Trial Profile
An exploratory Phase 2 double-blinded placebo-controlled study to investigate the safety and efficacy of inhaled nitric oxide/INOpulse in patients with Pulmonary Hypertension-Sarcoidosis (PH-Sarc)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary fibrosis; Pulmonary hypertension; Scleroderma
- Focus Therapeutic Use
- 19 Aug 2022 New trial record
- 15 Aug 2022 According to a Bellerophon Therapeutics media release, company received FDA clearance to conduct the study.